ES2139373T3 - Derivados de 4,9-etano-benzo(f)isoindol como inhibidores de farnesil transferasa. - Google Patents
Derivados de 4,9-etano-benzo(f)isoindol como inhibidores de farnesil transferasa.Info
- Publication number
- ES2139373T3 ES2139373T3 ES96924952T ES96924952T ES2139373T3 ES 2139373 T3 ES2139373 T3 ES 2139373T3 ES 96924952 T ES96924952 T ES 96924952T ES 96924952 T ES96924952 T ES 96924952T ES 2139373 T3 ES2139373 T3 ES 2139373T3
- Authority
- ES
- Spain
- Prior art keywords
- sub
- alcoil
- hydrogen
- replaced
- alcoiloxi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229950008696 farnesil Drugs 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 title 1
- QKDLQFSLLCQTOH-UHFFFAOYSA-N Trichodonin Natural products C1C(O)C2C3(COC(=O)C)C(C=O)C(C)(C)CCC3OC(=O)C22C(=O)C(=C)C1C2 QKDLQFSLLCQTOH-UHFFFAOYSA-N 0.000 title 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 abstract 8
- 239000001257 hydrogen Substances 0.000 abstract 8
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- -1 AMINO Chemical class 0.000 abstract 2
- LYXFCGCYJQCSRL-UHFFFAOYSA-N OOSO Chemical group OOSO LYXFCGCYJQCSRL-UHFFFAOYSA-N 0.000 abstract 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical compound C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 abstract 1
- 125000003178 carboxy group Chemical class [H]OC(*)=O 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical class [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/72—4,7-Endo-alkylene-iso-indoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
NUEVOS PRODUCTOS DE FORMULA GENERAL (I), PROCEDIMIENTO DE PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS INCORPORAN. EN LA FORMULA GENERAL (I), R REPRESENTA UN RADICAL DE FORMULA GENERAL - (CH SUB,2}) SUB,M} - X SUB,1} - (CH SUB,2}) SUB,N} Z, DONDE X SUB,1} = SIMPLE ENLACE U O O S, M = 0 O 1 Y N = 0, 1 O 2, PUDIENDO LOS RADICALES CH SUB,2} SER SUSTITUIDOS POR GRUPOS CARBOXI, ALCOXICARBONIL, CARBAMOIL, ALCOILCARBAMOIL, DIALCOILCARBAMOIL, AMINO, ALCOILAMINO O DIALCOILAMINO, Y Z REPRESENTA CARBOXY, COOR SUB,4} (R SUB,4} = ALCOIL) O CON (R SUB,5}) (R SUB,6}) (R SUB,5} = HIDROGENO O ALCOIL), R SUB,1} = HIDROGENO O ALCOIL EVENTUALMENTE SUSTITUIDO, O BIEN R SUB,5} = HIDROGENO O ALCOIL Y R SUB,6} = HIDROXI, ALCOILOXI EVENTUALMENTE SUSTITUIDO, O AMINO, O PO (OR SUB,7}) SUB,2} (R SUB,7} = HIDROGENO O ALCOIL), O UN RADICAL - NH - CO - T (T = HIDROGENO O ALCOIL) EVENTUALMENTE SUSTITUIDO, O BIEN UN RADICAL (A). R SUB,1} Y R SUB,2} = HIDROGENO O HALOGENO O ALCOIL, ALCOILOXI EVENTUALMENTE SUSTITUIDO, OBIEN R SUB,1} Y R SUB,2} SITUADOS EN ORTO UNO CON RESPECTO A OTRO, FORMAN UN HETEROANILLO QUE INCLUYE 1 O 2 HETEROATOMOS EVENTUALMENTE SUSTITUIDOS, O BIEN R SUB,1} = HIDROGENO O HALOGENO O ALCOIL, ALCOILOXI EVENTUALMENTE SUSTITUIDO, Y R SUB,2} = TIOALCOIL; R SUB,3} = HIDROGENO O HALOGENO O ALCOIL, ALCENIL, ALCOILOXI, ALCOILTIO, CARBOXI O ALCOILOXICARBONIL; X = O O S O - NH -, - CO -, METILENO, ETILENO, ALCOILIDENO O 1,1 - CICLOALCOIL, E Y = O O S. LOS NUEVOS PRODUCTOS DE FORMULA GENERAL (I) SON INHIBIDORES DE LA FARNESIL TRANSFERASA, QUE PRESENTAN NOTABLES PROPIEDADES ANTITUMORALES Y ANTILEUCEMICAS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9508296A FR2736641B1 (fr) | 1995-07-10 | 1995-07-10 | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2139373T3 true ES2139373T3 (es) | 2000-02-01 |
Family
ID=9480830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES96924952T Expired - Lifetime ES2139373T3 (es) | 1995-07-10 | 1996-07-08 | Derivados de 4,9-etano-benzo(f)isoindol como inhibidores de farnesil transferasa. |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US5936097A (es) |
| EP (1) | EP0839133B1 (es) |
| JP (1) | JPH11511123A (es) |
| KR (1) | KR19990028856A (es) |
| CN (1) | CN1096448C (es) |
| AR (1) | AR003143A1 (es) |
| AT (1) | ATE185341T1 (es) |
| AU (1) | AU712194B2 (es) |
| BR (1) | BR9609440A (es) |
| CA (1) | CA2224414A1 (es) |
| CO (1) | CO4700457A1 (es) |
| CZ (1) | CZ291620B6 (es) |
| DE (1) | DE69604588T2 (es) |
| DK (1) | DK0839133T3 (es) |
| EA (1) | EA000797B1 (es) |
| ES (1) | ES2139373T3 (es) |
| FR (1) | FR2736641B1 (es) |
| GR (1) | GR3031409T3 (es) |
| IL (1) | IL122812A (es) |
| MA (1) | MA23929A1 (es) |
| MX (1) | MX9800262A (es) |
| MY (1) | MY114792A (es) |
| NO (1) | NO309565B1 (es) |
| NZ (1) | NZ313211A (es) |
| PE (1) | PE11898A1 (es) |
| PL (1) | PL324430A1 (es) |
| SK (1) | SK282250B6 (es) |
| TN (1) | TNSN96098A1 (es) |
| TW (1) | TW438792B (es) |
| UY (1) | UY24276A1 (es) |
| WO (1) | WO1997003050A1 (es) |
| ZA (1) | ZA965868B (es) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6013662A (en) * | 1996-12-30 | 2000-01-11 | Rhone-Poulenc Rorer S.A. | Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments |
| FR2757855B1 (fr) * | 1996-12-30 | 1999-01-29 | Rhone Poulenc Rorer Sa | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent |
| US6124465A (en) * | 1997-11-25 | 2000-09-26 | Rhone-Poulenc S.A. | Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments |
| JP2001527078A (ja) * | 1997-12-23 | 2001-12-25 | アベンテイス・フアルマ・ソシエテ・アノニム | 新規なファルネシルトランスフェラーゼインヒビター、それらの製造、それらを含有する製薬学的組成物及び医薬品の製造のためのそれらの使用 |
| FR2772764B1 (fr) * | 1997-12-23 | 2000-01-14 | Rhone Poulenc Rorer Sa | Nouveaux inhibiteurs de farnesyle transferase, leur preparation, les compositions pharmaceutiques qui les contiennent et leur utilisation pour la preparation de medicaments |
| FR2787327B1 (fr) * | 1998-12-21 | 2003-01-17 | Aventis Pharma Sa | Compositions contenant des inhibiteurs de farnesyle transferase |
| FR2796641B1 (fr) | 1999-07-22 | 2001-09-21 | Aventis Pharma Sa | Nouveau procede de preparation de composes benzoperhydroisoindole |
| US20020177575A1 (en) * | 2001-05-04 | 2002-11-28 | Ward Wakeland | Identification of farnesyl-protein transferase as a target for systemic lupus erythematosus therapies |
| US8362075B2 (en) | 2005-05-17 | 2013-01-29 | Merck Sharp & Dohme Corp. | Cyclohexyl sulphones for treatment of cancer |
| TW200804345A (en) | 2005-08-30 | 2008-01-16 | Novartis Ag | Substituted benzimidazoles and methods of preparation |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| TW200813039A (en) | 2006-04-19 | 2008-03-16 | Novartis Ag | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling |
| JP5489333B2 (ja) | 2006-09-22 | 2014-05-14 | メルク・シャープ・アンド・ドーム・コーポレーション | 脂肪酸合成阻害剤を用いた治療の方法 |
| US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| CA2674436C (en) | 2007-01-10 | 2012-07-17 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors |
| AU2008221263B2 (en) | 2007-03-01 | 2012-02-23 | Novartis Ag | Pim kinase inhibitors and methods of their use |
| JP5378362B2 (ja) | 2007-05-21 | 2013-12-25 | ノバルティス アーゲー | Ｃｓｆ−１ｒ阻害剤、組成物および使用方法 |
| EP2170076B1 (en) | 2007-06-27 | 2016-05-18 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
| US7932036B1 (en) | 2008-03-12 | 2011-04-26 | Veridex, Llc | Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase |
| US8691825B2 (en) | 2009-04-01 | 2014-04-08 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
| CN102480966B (zh) | 2009-06-12 | 2015-09-16 | 达娜-法勃肿瘤研究所公司 | 融合的杂环化合物及其用途 |
| US8859776B2 (en) | 2009-10-14 | 2014-10-14 | Merck Sharp & Dohme Corp. | Substituted piperidines that increase p53 activity and the uses thereof |
| EP2937345B1 (en) | 2009-12-29 | 2018-03-21 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| JP2013522292A (ja) | 2010-03-16 | 2013-06-13 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | インダゾール化合物およびそれらの使用 |
| WO2011163330A1 (en) | 2010-06-24 | 2011-12-29 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
| AU2011282614B2 (en) | 2010-07-28 | 2015-11-26 | Janssen Pharmaceutica Nv | Methods of determining Acute Myeloid Leukemia response to treatment with farnesyltransferase inhibitors |
| CA2805265A1 (en) | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina) |
| HRP20191232T1 (hr) | 2010-08-17 | 2019-11-01 | Sirna Therapeutics Inc | Inhibicija, posredovana rna interferencijom, ekspresije gena virusa hepatitisa b (hbv) korištenjem kratkih interferirajućih nukleinskih kiselina (sina) |
| EP2608669B1 (en) | 2010-08-23 | 2016-06-22 | Merck Sharp & Dohme Corp. | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
| US8946216B2 (en) | 2010-09-01 | 2015-02-03 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
| US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
| DK2632472T3 (en) | 2010-10-29 | 2018-03-19 | Sirna Therapeutics Inc | RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA) |
| EP2654748B1 (en) | 2010-12-21 | 2016-07-27 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
| AU2012245455A1 (en) | 2011-04-21 | 2013-10-31 | Merck Sharp & Dohme Corp. | Insulin-Like Growth Factor-1 Receptor inhibitors |
| EP2770987B1 (en) | 2011-10-27 | 2018-04-04 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| JP6106685B2 (ja) | 2011-11-17 | 2017-04-05 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤 |
| EP2844261B1 (en) | 2012-05-02 | 2018-10-17 | Sirna Therapeutics, Inc. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
| JP6280554B2 (ja) | 2012-09-28 | 2018-02-14 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Ｅｒｋ阻害剤である新規化合物 |
| EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| US10000483B2 (en) | 2012-10-19 | 2018-06-19 | Dana-Farber Cancer Institute, Inc. | Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof |
| WO2014063061A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| AU2013352568B2 (en) | 2012-11-28 | 2019-09-19 | Merck Sharp & Dohme Llc | Compositions and methods for treating cancer |
| KR102196882B1 (ko) | 2012-12-20 | 2020-12-30 | 머크 샤프 앤드 돔 코포레이션 | Hdm2 억제제로서의 치환된 이미다조피리딘 |
| US9540377B2 (en) | 2013-01-30 | 2017-01-10 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as HDM2 inhibitors |
| US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| CN105849099B (zh) | 2013-10-18 | 2020-01-17 | 达纳-法伯癌症研究所股份有限公司 | 周期蛋白依赖性激酶7(cdk7)的多环抑制剂 |
| ES2676734T3 (es) | 2013-10-18 | 2018-07-24 | Syros Pharmaceuticals, Inc. | Compuestos heteroatómicos útiles para el tratamiento de enfermedades proliferativas |
| WO2015164614A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
| WO2015164604A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
| JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
| AU2015371251B2 (en) | 2014-12-23 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| JP6861166B2 (ja) | 2015-03-27 | 2021-04-21 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | サイクリン依存性キナーゼの阻害剤 |
| CA2986441A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| TWI621437B (zh) | 2015-08-17 | 2018-04-21 | 庫拉腫瘤技術股份有限公司 | 以法呢基轉移酶（farnesyltransferase）抑制劑治療癌症病患之方法 |
| CA2996978A1 (en) | 2015-09-09 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| JOP20190055A1 (ar) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | أجسام مضادة ضد cd27 |
| US10975084B2 (en) | 2016-10-12 | 2021-04-13 | Merck Sharp & Dohme Corp. | KDM5 inhibitors |
| LT3534885T (lt) | 2016-11-03 | 2021-07-12 | Kura Oncology, Inc. | Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui |
| EP3609922A2 (en) | 2017-04-13 | 2020-02-19 | Aduro Biotech Holdings, Europe B.V. | Anti-sirp alpha antibodies |
| WO2019094311A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| WO2019094312A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| WO2019113269A1 (en) | 2017-12-08 | 2019-06-13 | Kura Oncology, Inc. | Methods of treating cancer patients with farnesyltransferase inhibitors |
| WO2019148412A1 (en) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
| US12187701B2 (en) | 2018-06-25 | 2025-01-07 | Dana-Farber Cancer Institute, Inc. | Taire family kinase inhibitors and uses thereof |
| EP3833668B1 (en) | 2018-08-07 | 2025-03-19 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| CN112805006B (zh) | 2018-08-07 | 2024-09-24 | 默沙东有限责任公司 | Prmt5抑制剂 |
| EP3833667B1 (en) | 2018-08-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| AU2019413694B2 (en) | 2018-12-28 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
| US20220143006A1 (en) | 2019-03-15 | 2022-05-12 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
| US12441730B2 (en) | 2019-12-17 | 2025-10-14 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| EP4303246A1 (de) | 2022-07-04 | 2024-01-10 | Covestro Deutschland AG | Polyisocyanatgemisch |
| KR20250152667A (ko) | 2023-03-02 | 2025-10-23 | 카르치문 바이오테크 게엠베하 | 암 및/또는 급성 염증성 질환을 진단하는 수단 및 방법 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2492372A1 (fr) * | 1980-10-21 | 1982-04-23 | Cird | Dihydroxy-1,8 anthrones-9 substituees en position 10 et leur utilisation en medecine humaine ou veterinaire et en cosmetique |
| NZ275691A (en) * | 1993-11-05 | 1998-03-25 | Warner Lambert Co | Di and tripeptides and compositions thereof which inhibit farnesyl transferase |
-
1995
- 1995-07-10 FR FR9508296A patent/FR2736641B1/fr not_active Expired - Fee Related
-
1996
- 1996-07-03 MA MA24302A patent/MA23929A1/fr unknown
- 1996-07-04 PE PE1996000510A patent/PE11898A1/es not_active Application Discontinuation
- 1996-07-05 TW TW085108158A patent/TW438792B/zh not_active IP Right Cessation
- 1996-07-08 SK SK26-98A patent/SK282250B6/sk unknown
- 1996-07-08 AT AT96924952T patent/ATE185341T1/de not_active IP Right Cessation
- 1996-07-08 EP EP96924952A patent/EP0839133B1/fr not_active Expired - Lifetime
- 1996-07-08 CZ CZ199854A patent/CZ291620B6/cs not_active IP Right Cessation
- 1996-07-08 WO PCT/FR1996/001062 patent/WO1997003050A1/fr not_active Ceased
- 1996-07-08 CA CA002224414A patent/CA2224414A1/fr not_active Abandoned
- 1996-07-08 CN CN96195415A patent/CN1096448C/zh not_active Expired - Fee Related
- 1996-07-08 ES ES96924952T patent/ES2139373T3/es not_active Expired - Lifetime
- 1996-07-08 IL IL12281296A patent/IL122812A/en not_active IP Right Cessation
- 1996-07-08 NZ NZ313211A patent/NZ313211A/xx unknown
- 1996-07-08 DK DK96924952T patent/DK0839133T3/da active
- 1996-07-08 JP JP9505557A patent/JPH11511123A/ja active Pending
- 1996-07-08 KR KR1019980700157A patent/KR19990028856A/ko not_active Ceased
- 1996-07-08 MX MX9800262A patent/MX9800262A/es not_active IP Right Cessation
- 1996-07-08 BR BR9609440A patent/BR9609440A/pt not_active Application Discontinuation
- 1996-07-08 UY UY24276A patent/UY24276A1/es not_active IP Right Cessation
- 1996-07-08 US US08/981,840 patent/US5936097A/en not_active Expired - Fee Related
- 1996-07-08 DE DE69604588T patent/DE69604588T2/de not_active Expired - Fee Related
- 1996-07-08 PL PL96324430A patent/PL324430A1/xx unknown
- 1996-07-08 AU AU65224/96A patent/AU712194B2/en not_active Ceased
- 1996-07-08 EA EA199800118A patent/EA000797B1/ru not_active IP Right Cessation
- 1996-07-09 TN TNTNSN96098A patent/TNSN96098A1/fr unknown
- 1996-07-10 AR ARP960103511A patent/AR003143A1/es unknown
- 1996-07-10 CO CO96036152A patent/CO4700457A1/es unknown
- 1996-07-10 ZA ZA965868A patent/ZA965868B/xx unknown
- 1996-07-10 MY MYPI96002848A patent/MY114792A/en unknown
-
1998
- 1998-01-09 NO NO980094A patent/NO309565B1/no unknown
-
1999
- 1999-10-07 GR GR990402001T patent/GR3031409T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2139373T3 (es) | Derivados de 4,9-etano-benzo(f)isoindol como inhibidores de farnesil transferasa. | |
| ES2121836T3 (es) | Aminoguanidinas. | |
| ES2062460T3 (es) | Nuevos derivados de la isoindolona, su preparacion y las composiciones farmaceuticas que les contienen. | |
| ES2140075T3 (es) | Nuevos taxoides, su preparacion y las composiciones farmaceuticas que les contienen. | |
| MX9203338A (es) | Nuevos derivados del oxico a_nor-esteroide-3-carboxilico. | |
| ES2260933T3 (es) | Derivados del acido de tiazolina. | |
| ES2066808T3 (es) | Derivados de quinoleina, su produccion y uso. | |
| MX9400341A (es) | Derivados de los acidos quinolon- y naftiridon-carboxilicos, procedimiento para su obtencion y agentes antibacterianos y aditivos para piensos que los contienen. | |
| ES2040879T3 (es) | Procedimiento de preparacion de derivados pirimidinilaminicos de piperidina. | |
| ATE120764T1 (de) | Modifizierte polymere mit gemischten hydrophobischen gruppen. | |
| ES2099755T3 (es) | Derivados tripeptidicos de trifluorometilcetona. | |
| ES2159734T3 (es) | Derivados 2-heteroarilalquenilicos del acido ciclopentano-heptan(en)oico como agentes terapeuticos para el tratamiento de la hipertension ocular. | |
| DE3581768D1 (de) | Tensidepraeparate. | |
| ATE7138T1 (de) | Verfahren zur herstellung von 1,5-didesoxy-1,5imino-d-glucitol und dessen n-derivaten. | |
| ATE118580T1 (de) | Bauplatte und verfahren zur herstellung. | |
| ES2148758T3 (es) | Nuevos taxoides, su preparacion y las composiciones farmaceuticas que les contienen. | |
| ES2110423T3 (es) | Composiciones polimericas autoextinguentes. | |
| CO4980887A1 (es) | Nueva 3,4-diariltiazolina-2-uno o 2-tiono derivados, sus metodos de preparacion y su uso terapeutico | |
| ES2095068T3 (es) | Peroxicarbonatos polimericos y procedimiento para prepararlos. | |
| ES2057679T3 (es) | Piridinas substituidas. | |
| ES2059831T3 (es) | Producto radiofarmaceutico que tiene principalmente un tropismo cardiaco que comprende un complejo nitruro de un metal de transicion, y su procedimiento de preparacion. | |
| ES2151155T3 (es) | Nuevos taxoides, su preparacion y las composiciones farmaceuticas que les contienen. | |
| ES2028902T3 (es) | Procedimiento de preparacion de derivados del indano. | |
| ES2089157T3 (es) | Nuevos derivados de la 20,21-dinoreburnamenina, su procedimiento de preparacion y los nuevos productos intermedios asi obtenidos, su aplicacion como medicamentos y composiciones que los contienen. | |
| FI900991A0 (fi) | Aprotinhomologer och ett foerfarande foer producering av aprotin och aprotinhomologer i jaest. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 839133 Country of ref document: ES |